I take umbrage at "controveries" in the conference title. It reinforces the bps complaints (Fred Wolff, MD, referenced in one abstract) that fibro develops for secondary (e.g.monetary) gain, essentially.
This conference is a rehash, and speaking of hash, is sponsored only by a cannabis company.
The chairs of the conference are from Tel Aviv Medical Center and a doc in Italy with a smattering of elsewheres.
The controversy is that this conference's sole purpose is to promote investment in cannabis therapeutics, which is good, but why be sly about it.